Authorship, funding, disclosures
Additional authors on the paper include Nelson H. Knudsen, Giulia Escobar, Felix Korell, Tamina Kienka, Celeste Nobrega, Seth Anderson, Andrew Y. Cheng, Maria Zschummel, Alexander Armstrong, Amanda Bouffard, Michael C. Kann, Sadie Goncalves, Hans W. Pope, Mitra Pezeshki, Alexander Rojas, Juliette S. M. T. Suermondt, Merle Phillips, Trisha R. Berger, Sangwoo Park, Diego Salas-Benito, Elijah P. Darnell, Filippo Birocchi, Mark B. Leick, Rebecca C. Larson, John G. Doench, Debattama Sen, and Kathleen B. Yates.
Support for the study was provided by the National Institutes of Health (grant R01CA238268), the Krantz Breakthrough Award, the German Research Foundation (DFG; 466535590), the Gilead Sciences Research Scholar Program, the CRIS Foundation Out-Back Fellowship Programme (outback2021_6), the Spanish Society of Medical Oncology, the American-Italian Cancer Foundation, and the Italian Association for Cancer Research.
Maus, Knudson, Korell, Berger, and Manguso are inventors on patents filed by Mass General and the Broad Institute on these technologies. Maus is an inventor on patents related to adoptive cell therapies, held by Mass General (some licensed to ProMab and Luminary Therapeutics) and University of Pennsylvania (some licensed to Novartis). Maus holds equity in 2SeventyBio, A2 Biotherapeutics, AffyImmune, BendBio, CARGO Therapeutics, GBM newco, Model T bio, Neximmune, and Oncternal Therapeutics. Maus receives grant/research support from Kite Pharma, Moderna, and Sobi. Maus has served as a consultant for multiple companies involved in cell therapies. Manguso has received consulting or speaking fees from Bristol Myers Squibb, Gilead Sciences, and Immunai Therapeutics; has equity ownership in OncoRev; and receives research funding from Calico Life Sciences. Leick is an inventor on patents related to adoptive cell therapies, held by Mass General, and has served as a consultant for BioNTech and Cabaletta Bio. Leick holds equity in AbbVie. Larson is an inventor on patents related to adoptive cell therapies held by Mass General, has served as a consultant for Cargo, and is now an employee of Link Cell Therapies.